Trial Profile

A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym024 (Anti-CD73) as Monotherapy and in Combination With Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sym 021 (Primary) ; Sym 024 (Primary)
Indications Adenocarcinoma; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic ductal carcinoma; Peritoneal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Symphogen

09 Dec 2024 Status changed from active, no longer recruiting to completed.
18 Apr 2024 Planned End Date changed from 1 Jul 2024 to 1 Dec 2024.
18 Apr 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com